ANTH : Summary for Anthera Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets closed

Anthera Pharmaceuticals, Inc. (ANTH)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.43+0.02 (+4.95%)
At close: 4:00PM EDT

0.44 0.01 (1.18%)
After hours: 7:49PM EDT

People also watch
AVEOFOLDAPRIALIMCPRX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.41
Open0.41
Bid0.41 x 1500
Ask0.44 x 4000
Day's Range0.41 - 0.44
52 Week Range0.38 - 4.41
Volume2,811,047
Avg. Volume2,595,722
Market Cap34.74M
Beta2.86
PE Ratio (TTM)-0.27
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube5 hours ago

    ETFs with exposure to Anthera Pharmaceuticals, Inc. : March 27, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Anthera Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ANTH-US. Comparing the performance and risk of Anthera Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Shire (SHPG) Rare Disease Drug Gets Fast Track Designation
    Zacks4 days ago

    Shire (SHPG) Rare Disease Drug Gets Fast Track Designation

    Shire plc (SHPG) announced that the FDA has granted Fast Track designation for recombinant ADAMTS13 (SHP655) for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP).

  • Anthera Pharmaceuticals, Inc. :ANTH-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017
    Capital Cube6 days ago

    Anthera Pharmaceuticals, Inc. :ANTH-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017

    Categories: Yahoo Finance Get free summary analysis Anthera Pharmaceuticals, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Anthera Pharmaceuticals, Inc. – Meridian Bioscience, Inc. (VIVO-US) that have also reported for this period. Highlights Year-on-year change in operating cash flow of -58.28% is about the same ... Read more (Read more...)